0000358654
Donate

Reimbursement status:
No reimbursement

Cancer: Lymphocytic leukaemia

Indication:

Ponatinib is indicated in adult patients with • Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.

Reimbursement information:

EPAR/SmPC

Details

ATC category :
L01XE
L01XE Protein kinase inhibitors
EMA approval status :
Approved
EMA approval date :
2013-07-01
EMA conditional? :
No
EMA orphan? :
Yes
EMA biological? :
No